Assembly Biosciences (ASMB) vs Neurogene (NGNE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Neurogene (NGNE) has outperformed Assembly Biosciences (ASMB) over the past year, gaining 10.4% versus a loss of 42.4%. Over five years, ASMB leads with a -21.3% price change compared with -78.3% for NGNE. Neurogene is the larger company by market cap ($458.5 million vs $454.4 million), about 1.0 times the size, while Assembly Biosciences is growing revenue faster (+153.5% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASMB | NGNE |
|---|---|---|
| Share price | $22.19 | $22.15 |
| Market cap | $454.39M | $458.53M |
| 1-day change | -1.38% | -3.40% |
| YTD return | -34.75% | +7.52% |
| 1-year return | -42.36% | +10.42% |
| 5-year return | -21.31% | -78.33% |
| P/E ratio (TTM) | 29.59 | — |
| EPS (TTM) | $0.75 | $-5.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $72.30M | $0 |
| Revenue growth (YoY) | +153.52% | -100.00% |
| Net income (latest FY) | $-6.12M | $-90.35M |
| Operating margin | -16.76% | — |
| Net margin | -8.47% | — |
| 52-week high | $39.65 | $43.66 |
| 52-week low | $19.20 | $15.93 |
| Distance from 52-week high | -44.04% | -49.27% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +130.73% | +250.47% |
| Average volume | 309.38K | 307.78K |
| Shares outstanding | 20.48M | 20.70M |
| Employees | 73 | 131 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NGNE has outperformed ASMB by 52.8 percentage points over the past year.
- Assembly Biosciences grew revenue faster in its latest fiscal year (+153.52% vs -100.00%).
About Assembly Biosciences
ASMB stock →Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
About Neurogene
NGNE stock →Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees
ASMB vs NGNE FAQ
Which is bigger, Assembly Biosciences or Neurogene?
Neurogene (NGNE) is larger, with a market capitalization of $458.53M compared with $454.39M for Assembly Biosciences (ASMB).
Which stock has performed better over the past year, ASMB or NGNE?
NGNE returned +10.42% over the past 12 months, compared with -42.36% for ASMB (price return, excluding dividends). Past performance does not predict future results.
Are Assembly Biosciences and Neurogene in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.